Listicle
- Cameco’s 2Q adjusted EPS came in at C$0.14, missing the estimate of C$0.26.
- Revenue for the quarter was C$598 million, falling short of the estimated C$711.4 million.
- Uranium production totaled 7.1 million pounds.
- Results reflect normal quarterly variability and acquisition-related costs.
- Westinghouse performance reaffirms expectations despite some impacts on overall results.
- Cameco’s contract portfolio has commitments covering the next decade, averaging 29 million pounds per year from 2024-2028.
- The portfolio aligns production rates with market demand and supports a tier-one cost structure.
- Analyst ratings include 13 buys, 2 holds, and 0 sells.
A look at Cameco Corp Smart Scores
| Factor | Score | Magnitude |
|---|---|---|
| Value | 2 | |
| Dividend | 2 | |
| Growth | 5 | |
| Resilience | 2 | |
| Momentum | 4 | |
| OVERALL SMART SCORE | 3.0 |
Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma
Analysts using the Smartkarma Smart Scores have provided an overall positive outlook for Cameco Corp, a company that explores, mines, and refines uranium for use in nuclear power generation. The company has received a high score of 5 for Growth, indicating strong potential for expansion and development in the long term. This suggests that Cameco may experience significant growth opportunities in the coming years.
Additionally, Cameco Corp has scored a solid 4 for Momentum, reflecting positive market sentiment and upward trends in the company’s performance. These scores suggest that despite moderate scores in other areas such as Value and Resilience (2 each) and Dividend (2), Cameco Corp is well-positioned for growth and progress in the foreseeable future as it continues to operate on a global scale.
Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Analytics and News
- ✓ Events & Webinars
